DuraStat in the News

March 2023

DuraStat Awarded Breakthrough Technology Agreement with Premier, Inc.

AUSTIN, Texas, March 8, 2023 /PRNewswire/ — DuraStat LLC, a medical device company innovating in the area of surgical tissue closure, has been awarded a Breakthrough Technology group purchasing agreement with Premier, Inc. Effective March 15th the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for DuraStat. 

July 2022

DuraStat Receives Vizient Innovative Technology Contract for Dural Repair Device

AUSTIN, Texas, July 18, 2022 /PRNewswire/ — DuraStat LLC, a medical device company innovating in the area of surgical tissue closure, today announced it has received an Innovative Technology contract from Vizient, Inc. the nation’s largest member-driven health care performance improvement company. The agreement will expedite access to DuraStat’s flagship technology, a dural repair device for spine and neurosurgery, across Vizient’s membership of hospitals and surgery centers.

Apr 2022

DuraStat® Closes Financing to Reach All Spine Facilities with Flagship Product; Expedite New Products

AUSTIN, Texas, April 29, 2022 /PRNewswire/ — DuraStat LLC, a precision surgical tissue closure company, today announced closing over $5M in a Series B round to rapidly proliferate its flagship dural repair product to every spine facility and to accelerate upcoming product launches. The company plans to scale at 2-3x growth in 2022 with greater than 100% year-over-year growth anticipated in 2023 and beyond.


Nov 2020

DuraStat® Awarded Best New Technology in Spine by Orthopedics This Week

EXTON, Pa., Nov. 19, 2020 /PRNewswire/ — DuraStat LLC, a dural repair technology company, today announced receiving a Best Technology in Spine Award from Orthopedics This Week. “We thank Orthopedics This Week, and the independent panel of clinician evaluators for their recognition of DuraStat and its ability to contribute both to better outcomes for patients, and substantial cost savings for hospitals and ASCs.